Eupraxia Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Eupraxia Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11240
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Eupraxia Pharmaceuticals Inc (Eupraxia Pharma) is a drug development company that offers pain management solutions. The company’s technology encapsulates pharmaceutical micro particles in a polymer shell which helps to extend drug release from days to months. Its pipeline products include EP-104IAR and EP-104EPI. Eupraxia Pharma’s EP-104IAR is a sustained released non-opioid treatment for pain related to osteoarthritis. The company’s EP-104EPI is a non-opioid sustained release compounds for chronic pain indications. It provides a portfolio of drug candidates in the areas of osteoarthritis, chronic pain, anesthetic and antibiotic, veterinary health, post-surgical pain and anti-infectives. Eupraxia Pharma is headquartered in Victoria, British Columbia, Canada.

Eupraxia Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Eupraxia Pharma Raises Funds in Financing 10
Eupraxia Pharma Raises USD0.02 Million in Venture Financing 11
Eupraxia Pharma Raises Funds through Venture Financing 12
Eupraxia Pharma Raises USD0.4 Million in Venture Financing 13
Eupraxia Pharma Raises Funds through Venture Financing 14
Eupraxia Pharma Raises USD0.01 Million in Venture Financing 15
Licensing Agreements 16
Eupraxia Pharmaceuticals Enters into License Agreement with Auritec Pharmaceuticals 16
Eupraxia Pharmaceuticals Inc – Key Competitors 17
Eupraxia Pharmaceuticals Inc – Key Employees 18
Eupraxia Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eupraxia Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Eupraxia Pharma Raises Funds in Financing 10
Eupraxia Pharma Raises USD0.02 Million in Venture Financing 11
Eupraxia Pharma Raises Funds through Venture Financing 12
Eupraxia Pharma Raises USD0.4 Million in Venture Financing 13
Eupraxia Pharma Raises Funds through Venture Financing 14
Eupraxia Pharma Raises USD0.01 Million in Venture Financing 15
Eupraxia Pharmaceuticals Enters into License Agreement with Auritec Pharmaceuticals 16
Eupraxia Pharmaceuticals Inc, Key Competitors 17
Eupraxia Pharmaceuticals Inc, Key Employees 18

List of Figures
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Eupraxia Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Eupraxia Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aerovironment Inc:企業の戦略・SWOT・財務分析
    Aerovironment Inc - Strategy, SWOT and Corporate Finance Report Summary Aerovironment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Nickel Asia Corporation:企業の戦略・SWOT・財務情報
    Nickel Asia Corporation - Strategy, SWOT and Corporate Finance Report Summary Nickel Asia Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Seplat Petroleum Development Company Plc (SEPLAT):企業の財務・戦略的SWOT分析
    Seplat Petroleum Development Company Plc (SEPLAT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • EndoStim Inc:医療機器:M&Aディール及び事業提携情報
    Summary EndoStim Inc (EndoStim) is a medical device company that provides therapeutic solutions. The company develops and commercializes a neurostimulation system for the treatment of severe gastroesophageal reflux disease. It concentrates on the treatment of gastroesophageal reflux disease through …
  • Thien Viet Securities Joint Stock Company:企業の戦略的SWOT分析
    Thien Viet Securities Joint Stock Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Moberg Pharma AB (MOB):製薬・医療:M&Aディール及び事業提携情報
    Summary Moberg Pharma AB (Moberg Pharma), formerly Moberg Derma AB, is a pharmaceutical company. The company provides commercializes proprietary, acquired and licensed products. It provides treatment of skin diseases. Moberg Pharma treats fungal infection or psoriasis, discolored and fungus-damaged …
  • Biomatlante SA:企業の製品パイプライン分析
    Summary Biomatlante SA (Biomatlante) operates as a biologics solutions provider that manufactures, develops, and commercializes synthetic bone graft technologies and synthetic biomaterials for bone regeneration. The company’s products include inserts, granules, sticks, wedges, syringes, putty, screw …
  • GISA GmbH:企業の戦略的SWOT分析
    GISA GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • SteadyMed Therapeutics Inc:製品パイプライン分析
    Summary SteadyMed Therapeutics Inc (SteadyMed), a subsidiary of SteadyMed Ltd is a pharmaceutical company that develops and commercializes therapeutic product candidates. The company provides patchpump, a customizable, pre-filled, and pre-programmed disposable parenteral delivery platform for large …
  • Mitsubishi Ufj Financial Group Inc
    Mitsubishi Ufj Financial Group Inc - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Ufj Financial Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Kier Group plc:企業のM&A・事業提携・投資動向
    Kier Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Kier Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Kumba Iron Ore Ltd:企業の戦略・SWOT・財務情報
    Kumba Iron Ore Ltd - Strategy, SWOT and Corporate Finance Report Summary Kumba Iron Ore Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Sunkist Growers Inc:企業の戦略的SWOT分析
    Sunkist Growers Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • First Quantum Minerals Ltd:戦略・SWOT・企業財務分析
    First Quantum Minerals Ltd - Strategy, SWOT and Corporate Finance Report Summary First Quantum Minerals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Sentara Healthcare Inc:企業の戦略的SWOT分析
    Sentara Healthcare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • FOCUS Brands Inc.:企業の戦略・SWOT・財務情報
    FOCUS Brands Inc. - Strategy, SWOT and Corporate Finance Report Summary FOCUS Brands Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Forestar Group Inc:企業の戦略・SWOT・財務分析
    Forestar Group Inc - Strategy, SWOT and Corporate Finance Report Summary Forestar Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Polenergia SA (PEP):企業の財務・戦略的SWOT分析
    Polenergia SA (PEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Mercury NZ:企業の戦略・SWOT・財務情報
    Mercury NZ - Strategy, SWOT and Corporate Finance Report Summary Mercury NZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Range Resources Ltd (RRS):石油・ガス:M&Aディール及び事業提携情報
    Summary Range Resources Ltd (Range Resources) is an independent upstream oil and gas company. It explores, develops and produces oil and gas in Georgia, Guatemala and Trinidad. The company works on both onshore and offshore production and its onshore projects are operational through water injection. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆